Partner
Pier has represented parties in dozens of proceedings before the PTAB, including as lead arguing counsel. His experience includes inter partes review (IPR), interference, reexamination, and ex parte prosecution appeal proceedings involving a range of technologies, including monoclonal antibody pharmaceuticals and other biologics, small-molecule drugs, biofuels, solid-state materials for renewable energy devices, collaboration software, and internet security.
Pier has also represented pharmaceutical and chemical clients in a variety of litigation venues, including U.S. district courts, the Federal Circuit, arbitration, and the U.S. International Trade Commission (ITC). His litigation experience includes managing pre-suit investigations, conducting all stages of fact and expert discovery, acting as lead drafter of dispositive motions, and trial representation.
Pier particularly enjoys counseling innovative and growing clients on a diverse array of patent matters. He has prepared numerous validity, infringement, and freedom-to-operate opinions for clients in the life science and chemical fields, drawing on his extensive litigation background. He also has significant experience managing patent portfolios and providing strategic prosecution guidance in the chemical and electrical arts. Pier has been recognized as a Rising Star by Managing Intellectual Property (MIP) magazine.
A substantial portion of Pier's time is devoted to pro bono matters. He has represented disabled clients in several federal appeals, including as lead and backup counsel on amicus briefs before the Federal Circuit and the U.S. Supreme Court.
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
2020-1747, -1748, -1749, -1750, -1751, -1752, -1876, -1877, -1878, Fed. Cir.
Danisco US Inc. v. Novozymes A/S
IPR2019-01010, PTAB
Finnegan tees up valuable patents for Principia Biopharma, leading to major acquisition deal
Completed successful patent prosecution for Principia. By entrusting Finnegan to obtain strong patents for their Phase 1 candidate, Principia was able to secure an exclusive, worldwide license agreement with Sanofi to develop and commercialize PRN2246, with the potential for $765 million in milestone payments. Finnegan also successfully prosecuted patents directed to compound PRN1008, a BTK inhibitor that Principia is investigating for autoimmune and inflammatory diseases. Principia’s impressive pipeline of drug candidates, covered by a patent portfolio prosecuted by Finnegan, led to an IPO in which Principia raised over $100 million. Sanofi agreed to pay $3.7 billion to acquire Principia.
Eli Lilly and Company v. Teva Pharmaceuticals International
IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB
Sandoz Inc. v. AbbVie Biotechnology, Ltd
Successfully defended AbbVie in two IPRs related to methods of treating Crohn's and ulcerative colitis with Humira®, achieving non-institution decisions from the PTAB.
IPR2018-01987, -01988, PTAB, Judges Ankenbrand, Harlow, Mitchell
Cisco Systems, Inc. v. VirnetX, Inc.
95/001,679, 95/001,746, 95/001,792, 95/001,851, 95/001,856, USPTO, Judges Foster, Hughes, Peikari, Pokrzywa
Event
Patent Ownership and Inventorship: Avoiding Pitfalls in Defending Against Infringement and Enforcing Patents Patent Ownership and Inventorship: Avoiding Pitfalls in Defending Against Infringement and Enforcing Patents
August 03, 2023
Webinar
At the PTAB Blog
Finnegan Attorneys Author the Third Edition of The Practitioner’s Guide to Trials Before the Patent Trial and Appeal Board Finnegan Attorneys Author the Third Edition of The Practitioner’s Guide to Trials Before the Patent Trial and Appeal Board
November 28, 2022
Books
The Practitioner's Guide to Trials Before the Patent Trial and Appeal Board, Third Edition The Practitioner's Guide to Trials Before the Patent Trial and Appeal Board, Third Edition
September 2022
Podcasts
May 2020 - Last Month at the Federal Circuit Podcast Series May 2020 - Last Month at the Federal Circuit Podcast Series
May 31, 2020
Articles
Against the Odds—Prevailing on IPR Grounds Without Satisfying the ‘Reasonable Likelihood’ Standard Against the Odds—Prevailing on IPR Grounds Without Satisfying the ‘Reasonable Likelihood’ Standard
October 23, 2019
Bloomberg LawWebinar
Ready to Launch? IP Portfolio "Health Check" Workshop Ready to Launch? IP Portfolio "Health Check" Workshop
September 24, 2019
Webinar
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Managing Intellectual PropertyPress Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyPress Release
38 Finnegan Attorneys Named Managing Intellectual Property IP Stars; Firm Maintains Tier 1 Rankings 38 Finnegan Attorneys Named Managing Intellectual Property IP Stars; Firm Maintains Tier 1 Rankings
July 8, 2021
Managing Intellectual PropertyMedia Mention
Biogen MS Drug Patent Survives Mylan's PTAB Challenge Biogen MS Drug Patent Survives Mylan's PTAB Challenge
February 6, 2020
Law360Press Release
Finnegan Announces Seven New Partners Finnegan Announces Seven New Partners
January 1, 2020
Press Release
Managing Intellectual Property Names Five Finnegan Attorneys as 2019 Rising Stars Managing Intellectual Property Names Five Finnegan Attorneys as 2019 Rising Stars
December 16, 2019
Managing Intellectual PropertyDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.